Protein Kinase Inhibitors in Research and Medicine
Volume 548
Herausgegeben:Shokat, Kevan M
Protein Kinase Inhibitors in Research and Medicine
Volume 548
Herausgegeben:Shokat, Kevan M
- Gebundenes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers protein kinase inhibitors in research and medicine, and includes chapters on such topics as fragment-based screening, broad kinome profiling of kinase inhibitors, and designing drug-resistant kinase alleles.
Andere Kunden interessierten sich auch für
- Pseudokinases105,99 €
- Profiles of Drug Substances, Excipients, and Related Methodology135,99 €
- Pierfausto SeneciMolecular Targets in Protein Misfolding and Neurodegenerative Disease70,99 €
- G Protein Coupled Receptors113,99 €
- G Protein Coupled Receptors113,99 €
- Protein Prenylation, Part a96,99 €
- Khalil Ahmed / J.E. Allende / Olaf-Georg Issinger (Hgg.)Protein Kinase CK2 ¿ From Structure to Regulation79,99 €
-
-
-
This new volume of Methods in Enzymology continues the legacy of this premier serial with quality chapters authored by leaders in the field. This volume covers protein kinase inhibitors in research and medicine, and includes chapters on such topics as fragment-based screening, broad kinome profiling of kinase inhibitors, and designing drug-resistant kinase alleles.
Produktdetails
- Produktdetails
- Methods in Enzymology Volume 548
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: C2011-0-07294-0
- Seitenzahl: 252
- Erscheinungstermin: 4. Dezember 2014
- Englisch
- Abmessung: 242mm x 161mm x 19mm
- Gewicht: 610g
- ISBN-13: 9780123979186
- ISBN-10: 0123979188
- Artikelnr.: 37502606
- Methods in Enzymology Volume 548
- Verlag: Academic Press / Elsevier Science & Technology
- Artikelnr. des Verlages: C2011-0-07294-0
- Seitenzahl: 252
- Erscheinungstermin: 4. Dezember 2014
- Englisch
- Abmessung: 242mm x 161mm x 19mm
- Gewicht: 610g
- ISBN-13: 9780123979186
- ISBN-10: 0123979188
- Artikelnr.: 37502606
Professor Kevan is currently an Investigator of the Howard Hughes Medical Institute, Chair of the Department of Cellular and Molecular Pharmacology at UCSF and a Professor of Chemistry at UC Berkeley. He was inducted into the National Academy of Sciences (2010), the Institute of Medicine (2011), and the American Academy of Arts and Sciences (2011). His lab is most well-known for drugging the "undruggable" oncogene K-Ras (G12C) in 2013. In May of 2021 the drug sotorasib which binds to the same pocket on K-Ras (G12C) was approved for the treatment of lung cancer patients with this mutation. The field of K-Ras drug discovery is expanding quickly to hunt for drugs to target the other K-Ras mutants such as those which drive colon and pancreatic cancers which collectively represent almost 20% of all cancer patients world-wide. Kevan has been a co-founder of a number companies from their inception to public offering or acquisition and he is a co-founder of several currently private com
panies.
panies.
1. Catalytic Mechanisms and Regulation of Protein Kinases
Zhihong Wang and Philip A. Cole.
2. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
Qi Wang, Julie A. Zorn and John Kuriyan.
3. Fragment-Based Approaches to the Discovery of Kinase Inhibitors
Paul N. Mortenson, Valerio Berdini and Marc O'Reilly.
4. Targeting Protein Kinases with Selective and Semi-Promiscuous Covalent Inhibitors
Rand M. Miller and Jack Taunton.
5. The Resistance Tetrad: Amino Acid Hotspots for Kinome-Wide Exploitation of Drug-resistant Protein Kinase Alleles
Veselin I Andreev and Patrick A Eyers
6. FLiK: A Direct Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations
Jeffrey R. Simar and Daniel Rauh
7. Discovery of Allosteric Bcr-Abl inhibitors from Phenotypic Screen to Clinical Candidate
Nathanael S. Gray and Doriano Fabbro
8. The Logic and Design of Analog-Sensitive (AS) Kinases and their Small Molecule Inhibitors
Michael S. Lopez, Joseph Kliegman and Kevan M. Shokat
Zhihong Wang and Philip A. Cole.
2. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
Qi Wang, Julie A. Zorn and John Kuriyan.
3. Fragment-Based Approaches to the Discovery of Kinase Inhibitors
Paul N. Mortenson, Valerio Berdini and Marc O'Reilly.
4. Targeting Protein Kinases with Selective and Semi-Promiscuous Covalent Inhibitors
Rand M. Miller and Jack Taunton.
5. The Resistance Tetrad: Amino Acid Hotspots for Kinome-Wide Exploitation of Drug-resistant Protein Kinase Alleles
Veselin I Andreev and Patrick A Eyers
6. FLiK: A Direct Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations
Jeffrey R. Simar and Daniel Rauh
7. Discovery of Allosteric Bcr-Abl inhibitors from Phenotypic Screen to Clinical Candidate
Nathanael S. Gray and Doriano Fabbro
8. The Logic and Design of Analog-Sensitive (AS) Kinases and their Small Molecule Inhibitors
Michael S. Lopez, Joseph Kliegman and Kevan M. Shokat
1. Catalytic Mechanisms and Regulation of Protein Kinases
Zhihong Wang and Philip A. Cole.
2. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
Qi Wang, Julie A. Zorn and John Kuriyan.
3. Fragment-Based Approaches to the Discovery of Kinase Inhibitors
Paul N. Mortenson, Valerio Berdini and Marc O'Reilly.
4. Targeting Protein Kinases with Selective and Semi-Promiscuous Covalent Inhibitors
Rand M. Miller and Jack Taunton.
5. The Resistance Tetrad: Amino Acid Hotspots for Kinome-Wide Exploitation of Drug-resistant Protein Kinase Alleles
Veselin I Andreev and Patrick A Eyers
6. FLiK: A Direct Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations
Jeffrey R. Simar and Daniel Rauh
7. Discovery of Allosteric Bcr-Abl inhibitors from Phenotypic Screen to Clinical Candidate
Nathanael S. Gray and Doriano Fabbro
8. The Logic and Design of Analog-Sensitive (AS) Kinases and their Small Molecule Inhibitors
Michael S. Lopez, Joseph Kliegman and Kevan M. Shokat
Zhihong Wang and Philip A. Cole.
2. A Structural Atlas of Kinases Inhibited by Clinically Approved Drugs
Qi Wang, Julie A. Zorn and John Kuriyan.
3. Fragment-Based Approaches to the Discovery of Kinase Inhibitors
Paul N. Mortenson, Valerio Berdini and Marc O'Reilly.
4. Targeting Protein Kinases with Selective and Semi-Promiscuous Covalent Inhibitors
Rand M. Miller and Jack Taunton.
5. The Resistance Tetrad: Amino Acid Hotspots for Kinome-Wide Exploitation of Drug-resistant Protein Kinase Alleles
Veselin I Andreev and Patrick A Eyers
6. FLiK: A Direct Binding Assay for the Identification and Kinetic Characterization of Stabilizers of Inactive Kinase Conformations
Jeffrey R. Simar and Daniel Rauh
7. Discovery of Allosteric Bcr-Abl inhibitors from Phenotypic Screen to Clinical Candidate
Nathanael S. Gray and Doriano Fabbro
8. The Logic and Design of Analog-Sensitive (AS) Kinases and their Small Molecule Inhibitors
Michael S. Lopez, Joseph Kliegman and Kevan M. Shokat